Earlier in the week, I wrote about a cancer vaccine treatment that Stanford pathologist Edgar Engleman, MD, developed in the early 90s. As expected, the FDA gave the vaccine, called Provenge, the thumbs up today; according to Dow Jones (subscription required), the agency approved Provenge for patients with advanced prostate cancer who have failed hormone therapy treatment.
Popular posts
Genetics could explain why some people get severe COVID-19
Stanford Medicine researchers and others discovered 13 genetic signatures that are closely linked to an increased risk for severe COVID-19.
Can major surgery increase risk for Alzheimer’s disease?
During cardiac surgery, patients’ blood levels of a substance highly predictive of Alzheimer’s disease jumped more than 5-fold.